Reflex Sympathetic Dystrophy
A syndrome characterized by severe burning pain in an extremity accompanied by sudomotor, vasomotor, and trophic changes in bone without an associated specific nerve injury. This condition is most often precipitated by trauma to soft tissue or nerve complexes. The skin over the affected region is usually erythematous and demonstrates hypersensitivity to tactile stimuli and erythema. (Adams et al., Principles of Neurology, 6th ed, p1360; Pain 1995 Oct;63(1):127-33)
Drugs by status
Phase 4 trials (2)
Phase 3 trials (3)
Phase 2 trials (3)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (20)
- Takeda
- Celgene
- Millennium Pharmaceuticals
- Merck KGaA
- Novartis
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute of Nursing Research (NINR)
- Rockefeller University
- Drexel University
- McGill University
- Sorlandet Hospital HF
- University of California, Davis
- University of California, San Diego
- University of Sao Paulo
- Ludwig Maximilians University
- Department of Veteran Affairs
- German Federal Ministry of Education and Research
- Frontier Science & Technology Research Foundation, Inc.
- German Research Network on Neuropathic Pain
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (13)